Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Structure Therapeutics (NASDAQ:GPCR), maintaining a $65 price target.

May 03, 2024 | 3:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Structure Therapeutics, with a $65 price target.
The reaffirmation of an Overweight rating and a $65 price target by a reputable analyst like Prakhar Agrawal from Cantor Fitzgerald is likely to instill confidence among investors, potentially driving up the stock price in the short term. Analyst ratings, especially those that are maintained or upgraded, can have a significant positive impact on stock prices as they often influence investor perception and investment decisions.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100